# Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris

> **NCT00752635** · PHASE4 · COMPLETED · sponsor: **Johnson & Johnson Taiwan Ltd** · enrollment: 48 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol

## Key facts

- **NCT ID:** NCT00752635
- **Lead sponsor:** Johnson & Johnson Taiwan Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752635

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752635, "Comparison of Efficacy and Safety of Norgestimate-ethinyl Estradiol and Cyproterone Acetate-ethinyl Estradiol in the Treatment of Acne Vulgaris". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00752635. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*